Download PDF
Dtsch Med Wochenschr 2014; 139(49): 2503-2506
DOI: 10.1055/s-0034-1387407
Hämatologie & Onkologie | Commentary
Hämatologie, Onkologie
© Georg Thieme Verlag KG Stuttgart · New York

Aplastische Anämie

Aplastic anemia
H. Schrezenmeier
1   Institut für Klinische Transfusionsmedizin und Immungenetik Ulm
2   DRK-Blutspendedienst Baden-Württemberg-Hessen und Universitätsklinikum Ulm
3   Institut für Transfusionsmedizin, Universität Ulm
,
S. Körper
1   Institut für Klinische Transfusionsmedizin und Immungenetik Ulm
2   DRK-Blutspendedienst Baden-Württemberg-Hessen und Universitätsklinikum Ulm
3   Institut für Transfusionsmedizin, Universität Ulm
,
B. Höchsmann
1   Institut für Klinische Transfusionsmedizin und Immungenetik Ulm
2   DRK-Blutspendedienst Baden-Württemberg-Hessen und Universitätsklinikum Ulm
3   Institut für Transfusionsmedizin, Universität Ulm
› Author Affiliations
Further Information

Publication History

Publication Date:
25 November 2014 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

allogene Stammzelltransplantation - Immunsuppression - Antithymozytenglobulin - Eltrombopag - Telomere - Androgene

Keywords

allogenic stem cell transplantation - immunosuppresion - antithymocyte globulin - eltrombopag - telomeres - androgene
 

  • Literatur

  • 1 Afable MG, Tiu RV, Maciejewski JP. Clonal evolution in aplastic anemia. Hematology Am Soc Hematol Educ Program 2011; 2011: 90-95
    CrossrefPubMedGoogle Scholar
  • 2 Bacigalupo A, Socie G, Schrezenmeier H et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica 2012; 97: 1142-1148
    CrossrefPubMedGoogle Scholar
  • 3 Calado RT, Yewdell WT, Wilkerson KL et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood 2009; 114: 2236-2243
    CrossrefPubMedGoogle Scholar
  • 4 Desmond R, Townsley DM, Dumitriu B et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood 2014; 123: 1818-1825
    CrossrefPubMedGoogle Scholar
  • 5 Frickhofen N, Heimpel H, Kaltwasser JP et al. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003; 101: 1236-1242
    CrossrefPubMedGoogle Scholar
  • 6 Hochsmann B, Moicean A, Risitano A et al. Supportive care in severe and very severe aplastic anemia. Bone Marrow Transplant 2013; 48: 168-173
    CrossrefPubMedGoogle Scholar
  • 7 Hochsmann B, Rojewski M, Schrezenmeier H. Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes. Ann Hematol 2011; 90: 887-899
    CrossrefPubMedGoogle Scholar
  • 8 Kulasekararaj AG, Jiang J, Smith AE et al. Somatic mutations identify a sub-group of aplastic anemia patients that progress to myelodysplastic syndrome. Blood 2014; DOI: 10.1182/blood-2014-05-574889.
    PubMedGoogle Scholar
  • 9 Marsh JC, Bacigalupo A, Schrezenmeier H et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood 2012; 119: 5391-5396
    CrossrefPubMedGoogle Scholar
  • 10 Olnes MJ, Scheinberg P, Calvo KR et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 2012; 367: 11-19
    CrossrefPubMedGoogle Scholar
  • 11 Ruggero D, Shimamura A. Marrow failure: a window into ribosome biology. Blood 2014; DOI: 10.1182/blood-2014-04-526301.
    PubMedGoogle Scholar
  • 12 Samarasinghe S, Steward C, Hiwarkar P et al. Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience. Br J Haematol 2012; 10-2141
    PubMedGoogle Scholar
  • 13 Scheinberg P, Nunez O, Weinstein B et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011; 365: 430-438
    CrossrefPubMedGoogle Scholar
  • 14 Schrezenmeier H, Brümmendorf T, Linkesch W et al. Diagnostik und Therapie der erworbenen aplastischen Anämie. . Onkopedia-Leitlinien der Deutschen Gesellschaft für Hämatologie und medizinische Onkologie. 2013. www.dgho-onkopedia.de
    Google Scholar
  • 15 Schrezenmeier H, Passweg JR, Marsh JC et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007; 110: 1397-1400
    CrossrefPubMedGoogle Scholar
  • 16 Tichelli A, Schrezenmeier H, Socie G et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood 2011; 117: 4434-4441
    CrossrefPubMedGoogle Scholar
  • 17 Townsley DM, Dumitriu B, Young NS. Bone marrow failure and the telomeropathies. Blood 2014; DOI: 10.1182/blood-2014-05-526285.
    PubMedGoogle Scholar
  • 18 Ziegler P, Schrezenmeier H, Akkad J et al. Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation. Ann Hematol 2012; 91: 1115-1120
    CrossrefPubMedGoogle Scholar